Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258998 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| SCHEMBL6464207 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| SCHEMBL60323 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| SCHEMBL8587285 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| SCHEMBL2279600 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL17061382 | 0.98 | TDP1 (0.66) | TDP1ABCB1POLBMAPK1 | |
| SCHEMBL60713 | 0.95 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1 | |
| SCHEMBL13893402 | 0.95 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1 | |
| SCHEMBL421756 | 0.95 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1 | |
| SCHEMBL426635 | 0.95 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229771-B1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIV PALACKEHO (CZ) | 2024-04-03 | — | — | EP | disclosed |
| US-20230055475-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC (US) | 2023-02-23 | — | — | US | disclosed |
| EP-3229772-B1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIV PALACKEHO (CZ) | 2020-04-29 | — | — | EP | disclosed |
| US-10550144-B2 | 6-aryl-9-glycosylpurines and use thereof | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-02-04 | — | — | US | disclosed |
| US-10342811-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | SEATTLE GENETICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10100077-B2 | 6-aryl-9-glycosylpurines and use thereof | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2018-10-16 | — | — | US | disclosed |
| US-20170334943-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-11-23 | — | — | US | disclosed |
| US-20170326168-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-11-16 | — | — | US | disclosed |
| EP-3229771-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | Univerzita Palackého v Olomouci (CZ) | 2017-10-18 | — | — | EP | disclosed |
| EP-3229772-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | Univerzita Palackého v Olomouci (CZ) | 2017-10-18 | — | — | EP | disclosed |
| US-20170035790-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | SEATTLE GENETICS, INC. (US) | 2017-02-09 | — | — | US | disclosed |
| WO-2016091235-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016091236-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2016-06-16 | — | — | WO | disclosed |
| US-8993326-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEATTLE GENETICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140031536-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEATTLE GENETICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| CN-1278825-A | Sarcodictyin and eleutherobin useful for stabilising microtubules | NOVARTIS AG (CH) | 2001-01-03 | — | — | CN | disclosed |
| EP-1042328-A1 | SARCODICTYIN AND ELEUTHEROBIN DERIVATIVES USEFUL FOR STABILISING MICROTUBLES | Novartis AG (CH) | 2000-10-11 | — | — | EP | disclosed |
| US-5965718-A | Analogs of sarcodictyin and eleutherobin | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1999021862-A1 | SARCODICTYIN AND ELEUTHEROBIN USEFUL FOR STABILISING MICROTUBULES | NOVARTIS AG (CH) | 1999-05-06 | — | — | WO | disclosed |
| WO-1998040390-A2 | OLIGOSACCHARIDES AND THE DERIVATIVES THEREOF, CHEMO-ENZYMATIC METHOD FOR THE PRODUCTION THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031536-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | FUT5, FUCA2, FCGR3B | TDP1 4741/4885ABCB1 2049/4885POLB 3154/4885 |
| US-20170035790-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | FUCA1, FUCA2, FUT4 | TDP1 4730/4885ABCB1 3225/4885POLB 4562/4885 |
| US-20230055475-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | FUT5, FUCA2, FCGR3B | TDP1 4741/4885ABCB1 2049/4885POLB 3154/4885 |
| US-20170326168-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | GART, DAO, GLA | TDP1 808/4885ABCB1 2445/4885POLB 2484/4885 |
| US-10550144-B2 | 6-aryl-9-glycosylpurines and use thereof | GART, DAO, GLA | TDP1 808/4885ABCB1 2445/4885POLB 2484/4885 |
| US-20170334943-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNG, FUT6, GART | TDP1 575/4885ABCB1 951/4885POLB 1080/4885 |
| US-10342811-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | FUCA1, FUCA2, FUT4 | TDP1 4730/4885ABCB1 3225/4885POLB 4562/4885 |
| US-10100077-B2 | 6-aryl-9-glycosylpurines and use thereof | UNG, FUT6, GART | TDP1 575/4885ABCB1 951/4885POLB 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.